Talimogene laherparepvec (T-VEC), a second-generation type of oHSV expressing granulocyte macrophage colony-stimulating factor (GM-CSF), have received the first approval of the US Food and Drug Administration (FDA) for advanced melanoma patients [24]. The gene discussed is CSF2; the disease is melanoma.